Investigating the effect of amino selenium in the treatment of endometriosis

Phase 3

Recruiting

• Conditions: Endometriosis.; Endometriosis

• Registration Number: IRCT20110606006709N26
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 66

Inclusion Criteria

Women of reproductive age (15-49 years)
Being literate in reading and writing
Women with primary endometriosis with endometrioma less than 5 cm
Women with symptomatic endometriosis (dysmenorrhoea pain score of 16 or more in the Mous Menstrual Distress Questionnaire)
Married women who are sexually active

Exclusion Criteria

Probability of malignancy based on vaginal ultrasound
Definite need for surgery based on the opinion of obstetrician and gynecologist
Suffering from diseases such as myoma or hyperplasia or polycystic ovary syndrome based on vaginal ultrasound
Daily and regular consumption of supplements containing Amino Selenium during the last three months according to the patient's statement
Suffering from liver and kidney diseases and the need for dialysis
Pregnancy and breastfeeding
Desire to get pregnant in the next trimester
Allergy to Gelofen

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Average endometrioma cyst size. Timepoint: Before the intervention and 3 months after the start of intervention. Method of measurement: Vaginal ultrasound.;Average dysmenorrhea score. Timepoint: Monthly during 3 months (1, 2, 3 months) after the start of the intervention. Method of measurement: Mous Menstrual Distress Questionnaire (MMDQ).

Secondary Outcome Measures

Name	Time	Method
Average dyspareunia score. Timepoint: Monthly during 3 months (1, 2, 3 months) after the start of the intervention. Method of measurement: Visual analog scale (VAS).;Average score of dysuria. Timepoint: Monthly during 3 months (1, 2, 3 months) after the start of the intervention. Method of measurement: Visual analog scale (VAS).;Average score of Dyschezia. Timepoint: Monthly during 3 months (1, 2, 3 months) after the start of the intervention. Method of measurement: Visual analog scale (VAS).;Average score of non cyclic pain. Timepoint: Monthly during 3 months (1, 2, 3 months) after the start of the intervention. Method of measurement: Visual analog scale (VAS).